| INOV Etf | | | USD 28.88 0.06 0.21% |
Keith Dunleavy is Portfolio Manager at Innovator ETFs Trust
Dr. Keith R. Dunleavy, M.D., is Chairman of the Board, Chief Executive Officer of the INOVALON HOLDINGS, INC. Dr. Dunleavy has served as our Chief Executive Officer since his organization of our predecessor companies in 1998, as Chairman of the Board since the creation of the Board in 2006, and as President from our foundation until May of 2014. Dr. Dunleavy is responsible for the overall execution of our business plan, strategic relationships, and the identification and realization of our product strategy and vision. During his tenure building Inovalon, Dr. Dunleavy has worked extensively with a wide array and number of healthcare organizations, regulatory and oversight bodies, and technology companies examining the growing role of data within healthcare, and its ability to drive meaningful insight and improvement for its constituents. Dr. Dunleavy serves as a Director on the Dartmouth Medical School Board of Overseers, has authored or coauthored a number of scientific journal articles, abstracts, and proprietary research papers, and has presented his work and materials at multiple national and international conferences
| Age | 55 |
| Tenure | 18 years |
| Professional Marks | Ph.D |
| Phone | (215) 979-3750 |
| Web | http://www.inovalon.com |
Dunleavy received a Bachelor’s degree in Biology modified with Engineering with High Honors from Dartmouth College, where his studies and work focused upon the neurosciences, computer sciences and engineering, and his honors thesis focused on the computer simulation of artificial human cerebellar functional units. He earned his doctorate in medicine from Harvard Medical School, completed his medical residency at The Johns Hopkins Hospital in Baltimore, Maryland, and practiced and was Board Certified in Internal Medicine.
Innovator ETFs Management Efficiency
The company has return on total asset
(ROA) of
0.0331 % which means that it generated a profit of $0.0331 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
0.0716 %, meaning that it created $0.0716 on every $100 dollars invested by stockholders. Innovator ETFs' management efficiency ratios could be used to measure how well Innovator ETFs manages its routine affairs as well as how well it operates its assets and liabilities.
Innovator ETFs Trust currently holds 897.3
M in liabilities with Debt to Equity
(D/E) ratio of 1.39, which is about average as compared to similar companies. Innovator ETFs Trust has a current ratio of 2.13, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Debt can assist Innovator ETFs until it has trouble settling it off, either with new capital or with free cash flow. So, Innovator ETFs' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovator ETFs Trust sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovator to invest in growth at high rates of return. When we think about Innovator ETFs' use of debt, we should always consider it together with cash and equity.
Inovalon Holdings, Inc. provides cloud-based platforms for data-driven healthcare. Inovalon Holdings, Inc. was founded in 1998 and is headquartered in Bowie, Maryland. Inovalon Hlds operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 1836 people. Innovator ETFs Trust [INOV] is traded in USA and was established null.
Management Performance
Innovator ETFs Trust Money Managers
| Paige MD, Chief Officer | |
| Eric Sullivan, VP Strategies | |
| Hulus Alpay, VP Relations | |
| Geoff Charron, Chief Officer | |
| Keith Dunleavy, Chairman of the Board, CEO | |
| Kim Collins, Sr Communications | |
| Beverly Allen, Chief Counsel | |
| Jonathan CPA, Chief Officer | |
| Eron Kelly, Co Pres | |
| Ingrid Olsen, Chief Officer | |
Innovator Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is Innovator ETFs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
When determining whether Innovator ETFs Trust offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innovator ETFs'
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innovator Etfs Trust Etf.
Outlined below are crucial reports that will aid in making a well-informed decision on Innovator Etfs Trust Etf: Check out
Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innovator ETFs Trust. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as
signals in persons.
You can also try the
FinTech Suite module to use AI to screen and filter profitable investment opportunities.
The market value of Innovator ETFs Trust is measured differently than its book value, which is the value of Innovator that is recorded on the company's balance sheet. Investors also form their own opinion of Innovator ETFs' value that differs from its market value or its book value, called intrinsic value, which is Innovator ETFs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innovator ETFs' market value can be influenced by many factors that don't directly affect Innovator ETFs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innovator ETFs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Innovator ETFs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innovator ETFs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.